S1674 Recurrent Acute Pancreatitis Following COVID-19 Vaccine – A Case Study

Brittain, Connor; Christian, Victoria; Mahaseth, Harishchandra; Vadlamudi, Raja

doi:10.14309/01.ajg.0000780228.89609.37

Cited by 6 publications

(15 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 20 Similarly, in the case of acute pancreatitis following both doses of vaccination, offending medication may also have contributed to development of the acute pancreatitis. 21 In our case, acute pancreatitis occurred after a short while after receiving the third dose of the vaccine, without evidence of consumption of alcoholic beverages, cholelithiasis, hypertriglyceridemia, hypercalcemia, or trauma. Although potential side effects of medications such as mesalasine and pantoprazole may have been the etiology of acute pancreatitis in our case, long-term use of these medications in our case rather than recent initiation of the agents may make them less likely to be the cause of acute pancreatitis.…”

Section: Discussionmentioning

confidence: 56%

“…These cases occurred within few hours to days following administration of the first or second dose of BNT162b2 vaccine. [18][19][20][21] Of note, in one case, acute pancreatitis occurred after both first and second doses of the vaccination. 21 Nevertheless, the association of COVID-19 vaccination and acute pancreatitis and its potential etiologic role is not clear in such cases.…”

Section: Discussionmentioning

confidence: 99%

“…[18][19][20][21] Of note, in one case, acute pancreatitis occurred after both first and second doses of the vaccination. 21 Nevertheless, the association of COVID-19 vaccination and acute pancreatitis and its potential etiologic role is not clear in such cases. For instance, in one of the cases, 19 the diagnosis of acute pancreatitis is questionable based on Atlanta classification, 22 since despite the symptoms and elevation of urine amylase, serum amylase was not elevated more than three times of normal limits and also ultrasound and magnetic resonance imaging did not suggest pancreatic inflammation.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Acute pancreatitis as an adverse effect of COVID-19 vaccination

Cacdac

Jamali

et al. 2022

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

While vaccination against COVID-19 has significantly improved the morbidity and mortality of the disease, with the increase in the administration of COVID-19 vaccines, it is more likely to observe their rare side effects in the clinical settings. Herein, we report a case of an 82-year-old man with history of coronary artery disease, prostate cancer in remission, gastroesophageal reflux disease, and hypothyroidism, who presented with acute pancreatitis few hours after receiving the third dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine, without other identified etiology. His symptoms were mild and he was discharged in a stable condition after improvement in his condition with supportive care.

show abstract

Section: Discussionmentioning

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Acute pancreatitis as an adverse effect of COVID-19 vaccination

Cacdac

Jamali

et al. 2022

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

show abstract

“…This global initiative of promoting vaccinations must move forward to stop this pandemic, which has affected lives worldwide. Although developed, tested, and approved in record time, the COVID-19 vaccines are very effective and safe, and SAEs are extremely rare [ 10 , 11 , 12 , 16 , 18 ]. However, owing to the pressing need to control the spread of the virus, any long-term vaccination-associated SAEs that were initially missed (due to lack of long-term data) in the original vaccine trials will become evident in the long term from the emerging real-world data.…”

Section: Discussionmentioning

confidence: 99%

“…Interestingly, pancreatic injury/acute pancreatitis (in some cases recurrent pancreatitis) were reported in individuals following COVID-19 vaccine administration and could be a possible cause for postvaccination hyperglycemia in the affected individuals [ 16 , 17 , 18 , 19 ]. There is a possibility that inflammatory mechanisms (elevation of proinflammatory cytokines, such as IL-1, IL-6, IFNγ, and TNFα) in response to a trigger (such as vaccine excipients), the adenoviral vector (as in the case of the Covishield vaccine), or the SARS-CoV-2 spike protein immunogen (derived from the vaccine) may culminate in pancreatic endocrine system damage and subsequently in an acute hyperglycemic milieu ( Figure 1 ) [ 8 , 11 , 12 ].…”

Section: Possible Mechanism(s) Of Vihgmentioning

confidence: 99%

COVID-19 Vaccines and Hyperglycemia—Is There a Need for Postvaccination Surveillance?

et al. 2022

View full text Add to dashboard Cite

The COVID-19 vaccines currently in use have undoubtedly played the most significant role in combating the SARS-CoV-2 virus and reducing disease severity and the risk of death among those affected, especially among those with pre-existing conditions, such as diabetes. The management of blood glucose levels has become critical in the context of the COVID-19 pandemic, where data show two- to threefold higher intensive care hospital admissions and more than twice the mortality rate among diabetic COVID-19 patients when compared with their nondiabetic counterparts. Furthermore, new-onset diabetes and severe hyperglycemia-related complications, such as hyperosmolar hyperglycemic syndrome (HHS) and diabetic ketoacidosis (DKA), were reported in COVID-19 patients. However, irrespective of the kind of vaccine and dosage number, possible vaccination-induced hyperglycemia and associated complications were reported among vaccinated individuals. The current article summarizes the available case reports on COVID-19 vaccination-induced hyperglycemia, the possible molecular mechanism responsible for this phenomenon, and the outstanding questions that need to be addressed and discusses the need to identify at-risk individuals and promote postvaccination monitoring/surveillance among at-risk individuals.

show abstract

COVID-19-Vaccine-Pfizer-BioNTech

2021

Reactions Weekly

View full text Add to dashboard Cite

Acute pancreatitis: case reportA 46-year-old man developed acute pancreatitis following administration of COVID-19-Vaccine-Pfizer-BioNTech for COVID-19 vaccination. Later, he developed recurrent acute pancreatitis following administration of COVID-19-Vaccine-Pfizer-BioNTech for COVID-19 vaccination [route and dosages not stated].The man presented after experiencing upper abdominal pain, nausea and vomiting for 2 days after the first dose of COVID-19-Vaccine-Pfizer-BioNTech [Pfizer-BioNTech COVID-19 mRNA vaccine]. His symptoms worsened gradually, which led to hospitalisation. Subsequently, he was diagnosed with acute pancreatitis. His regular medications included lisinopril and hydrochlorothiazide. He had been consuming alcohol [beer]. Laboratory investigations showed lipase 648 U/L. The CT-scan revealed uncomplicated acute pancreatitis involving the distal body and tail of the pancreas.The man was kept NPO and was managed with unspecified IV fluids and analgesics and was discharged after improvement. He advised to stop alcohol. On the day of discharge, his lipase level was 45 U/L.The man did well until he received second dose of COVID-19-Vaccine-Pfizer-BioNTech. He developed similar symptoms of upper abdominal pain as he had reported previously. His pain continued to worsen, which led to hospitalisation for the second time. Laboratory investigations showed lipase 1483 U/L. The abdominal CT-scan revealed peripancreatic inflammatory changes with a 5cm complex thick-walled pseudocyst or walled off necrosis given the internal debris, which was consistent with recurrent acute pancreatitis. He was again kept NPO and treated with unspecified analgesics and IV fluids. Lisinopril and hydrochlorothiazide were discontinued and he was discharged with amlodipine. On the day of discharge, his lipase level was 233 U/L. Thus, both the episodes of acute pancreatitis were related to COVID-19 vaccination.

show abstract

S1674 Recurrent Acute Pancreatitis Following COVID-19 Vaccine – A Case Study

Cited by 6 publications

References 1 publication

Acute pancreatitis as an adverse effect of COVID-19 vaccination

Acute pancreatitis as an adverse effect of COVID-19 vaccination

COVID-19 Vaccines and Hyperglycemia—Is There a Need for Postvaccination Surveillance?

COVID-19-Vaccine-Pfizer-BioNTech

Contact Info

Product

Resources

About